[go: up one dir, main page]

WO2009053597A3 - Novel method for preparing nanoparticles covered with an organic stabilising layer coupled to targeting ligands - Google Patents

Novel method for preparing nanoparticles covered with an organic stabilising layer coupled to targeting ligands Download PDF

Info

Publication number
WO2009053597A3
WO2009053597A3 PCT/FR2008/051803 FR2008051803W WO2009053597A3 WO 2009053597 A3 WO2009053597 A3 WO 2009053597A3 FR 2008051803 W FR2008051803 W FR 2008051803W WO 2009053597 A3 WO2009053597 A3 WO 2009053597A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel method
layer coupled
preparing nanoparticles
targeting ligands
stabilising layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2008/051803
Other languages
French (fr)
Other versions
WO2009053597A2 (en
Inventor
Marc Port
Olivier Rousseaux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guerbet SA
Original Assignee
Guerbet SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guerbet SA filed Critical Guerbet SA
Publication of WO2009053597A2 publication Critical patent/WO2009053597A2/en
Publication of WO2009053597A3 publication Critical patent/WO2009053597A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1842—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a phosphate or a phosphonate, not being a phospholipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to a novel method for preparing nanoparticles for medical imaging, including a metal core, an organic stabilising layer and at least one ligand for targeting diseased tissue.
PCT/FR2008/051803 2007-10-05 2008-10-06 Novel method for preparing nanoparticles covered with an organic stabilising layer coupled to targeting ligands Ceased WO2009053597A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0758102A FR2921837B1 (en) 2007-10-05 2007-10-05 NOVEL PROCESS FOR THE PREPARATION OF NANOPARTICLES COVERED WITH AN ORGANIC STABILIZER LAYER COUPLED WITH TARGETING LIGANDS
FR0758102 2007-10-05

Publications (2)

Publication Number Publication Date
WO2009053597A2 WO2009053597A2 (en) 2009-04-30
WO2009053597A3 true WO2009053597A3 (en) 2009-10-15

Family

ID=39513512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/051803 Ceased WO2009053597A2 (en) 2007-10-05 2008-10-06 Novel method for preparing nanoparticles covered with an organic stabilising layer coupled to targeting ligands

Country Status (2)

Country Link
FR (1) FR2921837B1 (en)
WO (1) WO2009053597A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2921838A1 (en) 2007-10-05 2009-04-10 Guerbet Sa NOVEL PROCESS FOR THE PREPARATION OF NANOPARTICLES COVERED WITH A GEM-BISPHOSPHONATE STABILIZING LAYER COUPLED WITH HYDROPHILIC BIODISTRIBUTION LIGANDS
WO2011053252A1 (en) * 2009-10-28 2011-05-05 Agency For Science, Technology And Research Polymer coated magnetic particles
US20140065067A1 (en) 2010-12-17 2014-03-06 Universite De Strasbourg Radiopaque iodinated products intended for use medical imaging and their methods
WO2013121284A1 (en) 2012-02-14 2013-08-22 Universite De Strasbourg Iodinated products intended for a use for the medical imaging and their methods of preparation
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
CN116947829B (en) * 2023-07-05 2025-09-23 上海内瑟汐医疗科技有限公司 A fluorescent compound based on new indocyanine green IR820 and its preparation and application

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5160725A (en) * 1987-03-24 1992-11-03 Silica Gel Gesellschaft Mbh Adsorptions-Technik, Apparatebau Magnetic liquid compositions
WO1997001760A1 (en) * 1995-06-29 1997-01-16 Universite Pierre Et Marie Curie (Paris Vi) Magnetic nanoparticles coupled to annexine, and utilization thereof
US6638494B1 (en) * 1996-03-18 2003-10-28 Herbert Pilgrimm Super-paramagnetic particles with increased R1 relaxivity, process for producing said particles and use thereof
US20030229280A1 (en) * 2002-05-22 2003-12-11 Eucro European Contract Research Gmbh And Co. Kg Contrast Medium for Use in Imaging Methods
WO2004058275A2 (en) * 2002-12-20 2004-07-15 Guerbet Compositions of magnetic particles covered with gem-bisphosphonate derivatives
WO2004112840A2 (en) * 2003-06-25 2004-12-29 Guerbet Peptide conjugate for magnetic resonance imaging
FR2861994A1 (en) * 2003-11-12 2005-05-13 Guerbet Sa Using coated magnetic oxide particles for diagnosis or treatment of diseases in which matrix metalloproteases are implicated e.g. atheromous plaque or cancers, do not include targeting agent
WO2006031190A1 (en) * 2004-09-14 2006-03-23 Optoqrit Ab Superparamagnetic gadolinium oxide nanoscale particles and compositions comprising such particles
US20060216239A1 (en) * 2005-03-18 2006-09-28 Washington, University Of Magnetic nanoparticle compositions and methods
US20070190179A1 (en) * 2006-02-16 2007-08-16 Institute Of Nuclear Energy Research Atomic Energy Council Lipiodol-ferrofluid, and a process for preparation thereof
WO2008070459A2 (en) * 2006-11-22 2008-06-12 Alnis Biosciences, Inc. Coated nanoparticles for aqueous systems
WO2008115854A2 (en) * 2007-03-19 2008-09-25 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Multifunctional nanoparticles and compositions and methods of use thereof
WO2008125422A2 (en) * 2007-03-22 2008-10-23 Guerbet Use of metal nanoparticles for diagnosing alzheimer disease
WO2008125464A1 (en) * 2007-03-28 2008-10-23 Guerbet Compounds for the diagnosis of diseases associated with vcam expression
WO2008125420A2 (en) * 2007-03-28 2008-10-23 Guerbet Compounds for diagnosing apoptosis
WO2009035657A1 (en) * 2007-09-12 2009-03-19 Qd Vision, Inc. Functionalized nanoparticles and method
WO2009036441A2 (en) * 2007-09-14 2009-03-19 Northwestern University Contrast agents
WO2009053596A2 (en) * 2007-10-05 2009-04-30 Guerbet Novel method for preparing nanoparticles covered with a gem-bisphosphonate stabilising layer coupled to hydrophilic biodistribution ligands

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5160725A (en) * 1987-03-24 1992-11-03 Silica Gel Gesellschaft Mbh Adsorptions-Technik, Apparatebau Magnetic liquid compositions
WO1997001760A1 (en) * 1995-06-29 1997-01-16 Universite Pierre Et Marie Curie (Paris Vi) Magnetic nanoparticles coupled to annexine, and utilization thereof
US6638494B1 (en) * 1996-03-18 2003-10-28 Herbert Pilgrimm Super-paramagnetic particles with increased R1 relaxivity, process for producing said particles and use thereof
US20030229280A1 (en) * 2002-05-22 2003-12-11 Eucro European Contract Research Gmbh And Co. Kg Contrast Medium for Use in Imaging Methods
WO2004058275A2 (en) * 2002-12-20 2004-07-15 Guerbet Compositions of magnetic particles covered with gem-bisphosphonate derivatives
WO2004112840A2 (en) * 2003-06-25 2004-12-29 Guerbet Peptide conjugate for magnetic resonance imaging
FR2861994A1 (en) * 2003-11-12 2005-05-13 Guerbet Sa Using coated magnetic oxide particles for diagnosis or treatment of diseases in which matrix metalloproteases are implicated e.g. atheromous plaque or cancers, do not include targeting agent
WO2006031190A1 (en) * 2004-09-14 2006-03-23 Optoqrit Ab Superparamagnetic gadolinium oxide nanoscale particles and compositions comprising such particles
US20060216239A1 (en) * 2005-03-18 2006-09-28 Washington, University Of Magnetic nanoparticle compositions and methods
US20070190179A1 (en) * 2006-02-16 2007-08-16 Institute Of Nuclear Energy Research Atomic Energy Council Lipiodol-ferrofluid, and a process for preparation thereof
WO2008070459A2 (en) * 2006-11-22 2008-06-12 Alnis Biosciences, Inc. Coated nanoparticles for aqueous systems
WO2008115854A2 (en) * 2007-03-19 2008-09-25 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Multifunctional nanoparticles and compositions and methods of use thereof
WO2008125422A2 (en) * 2007-03-22 2008-10-23 Guerbet Use of metal nanoparticles for diagnosing alzheimer disease
WO2008125464A1 (en) * 2007-03-28 2008-10-23 Guerbet Compounds for the diagnosis of diseases associated with vcam expression
WO2008125420A2 (en) * 2007-03-28 2008-10-23 Guerbet Compounds for diagnosing apoptosis
WO2009035657A1 (en) * 2007-09-12 2009-03-19 Qd Vision, Inc. Functionalized nanoparticles and method
WO2009036441A2 (en) * 2007-09-14 2009-03-19 Northwestern University Contrast agents
WO2009053596A2 (en) * 2007-10-05 2009-04-30 Guerbet Novel method for preparing nanoparticles covered with a gem-bisphosphonate stabilising layer coupled to hydrophilic biodistribution ligands

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
PORTET D ET AL: "NONPOLYMERIC COATINGS OF IRON OXIDE COLLOIDS FOR BIOLOGICAL USE AS MAGNETIC RESONANCE IMAGING CONTRAST AGENTS", JOURNAL OF COLLOID AND INTERFACE SCIENCE, ACADEMIC PRESS, NEW YORK, NY, US, vol. 238, no. 1, 1 July 2001 (2001-07-01), pages 37 - 42, XP001162799, ISSN: 0021-9797 *
TIE ET AL: "Amino acid-coated nano-sized magnetite particles prepared by two-step transformation", COLLOIDS AND SURFACES. A, PHYSICACHEMICAL AND ENGINEERING ASPECTS, ELSEVIER, AMSTERDAM, NL, vol. 273, no. 1-3, 1 February 2006 (2006-02-01), pages 75 - 83, XP005229186, ISSN: 0927-7757 *
TIEFENAUER L X ET AL: "In Vivo Evaluation of Magnetic Nanoparticles For Use as a Tumor Contrast Agent in MRI", MAGNETIC RESONANCE IMAGING, TARRYTOWN, NY, US, vol. 14, no. 4, 1 January 1996 (1996-01-01), pages 391 - 402, XP003013148, ISSN: 0730-725X *
WANG LING ET AL: "A Biocompatible Method of Decorporation: Bisphosphonate-Modified Magnetite Nanoparticles to Remove Uranyl Ions from Blood", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, US, vol. 128, no. 41, 1 January 2006 (2006-01-01), pages 13358 - 13359, XP002475442, ISSN: 0002-7863 *

Also Published As

Publication number Publication date
FR2921837B1 (en) 2015-07-31
WO2009053597A2 (en) 2009-04-30
FR2921837A1 (en) 2009-04-10

Similar Documents

Publication Publication Date Title
WO2009053596A3 (en) Novel method for preparing nanoparticles covered with a gem-bisphosphonate stabilising layer coupled to hydrophilic biodistribution ligands
WO2009120247A3 (en) Lipid nanoparticle compositions and methods of making and using the same
IL194290A (en) Rna complex comprising a core double stranded region, a pharmaceutical compound comprising the same, a methof for preparing the same and uses thereof
IL238438A (en) 2,2,2-trifluoroacetophenones and method for preparing the same
NL1033936A1 (en) X-ray CT equipment.
NL1033652A1 (en) X-ray CT equipment.
SI2376537T1 (en) Human antibodies against human tissue factor.
IL190832A0 (en) Composite nanoparticles, nanoparticles, nanoparticles and methods for producing same
AP2011005740A0 (en) Pirfenidone treatment for patients with a typical liver function.
AP00409S1 (en) Multidose Inhaler.
WO2009053597A3 (en) Novel method for preparing nanoparticles covered with an organic stabilising layer coupled to targeting ligands
WO2006011810A3 (en) Mr imaging method for the discrimination between healthy and tumour tissue
TWI348967B (en) Metallic laminate and method for preparing the same
WO2008089397A3 (en) Adrb2 cancer markers
IL210955A0 (en) Method for characterizing. in particular for quantifying, molecular markers that are intracellularly absorbed from tissues by blood macrophages that are recirculated from the tissues into circulatory system
NL1034066A1 (en) X-ray CT equipment.
WO2008043101A3 (en) Intraoperative imaging of hepatobiliary structures
AP2010005389A0 (en) Nanoparticle carriers for drug administration and process for producing same.
EP2004373A4 (en) Method for producing sintered body, and sintered body
NL1032581A1 (en) X-ray CT equipment.
IL210030A0 (en) Novel imino derivatives, methods for producing the same and insecticides containing the same
PL1934252T3 (en) Process for the preparation of insulin conjugates.
AP2010005435A0 (en) 1,4-Naphthoquinone derivatives and therapeutic usethereof.
AP2010005479A0 (en) Phospohorous pentoxide producing methods.
SMT201200045B (en) External coating for coffins, sarcophagi, cinerary urns and the like

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08843326

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08843326

Country of ref document: EP

Kind code of ref document: A2